Marco Caremi - Newron Pharmaceuticals Exec Devel
| NWRN Stock | CHF 7.60 0.23 2.94% |
Insider
Marco Caremi is Exec Devel of Newron Pharmaceuticals SpA
| Age | 66 |
| Phone | 39 02 610 3461 |
| Web | https://www.newron.com |
Newron Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.1636) % which means that it has lost $0.1636 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (8.398) %, meaning that it generated substantial loss on money invested by shareholders. Newron Pharmaceuticals' management efficiency ratios could be used to measure how well Newron Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Peer Schroder | Basilea Pharmaceutica AG | N/A | |
| K Dahlstroem | VAT Group AG | N/A | |
| J Haggerty | VAT Group AG | N/A | |
| Lutz Wevelsiep | Basilea Pharmaceutica AG | N/A | |
| Sanna Fowler | Lonza Group AG | N/A | |
| M Zickar | VAT Group AG | N/A | |
| J Zoller | VAT Group AG | N/A | |
| Laurenz Kellenberger | Basilea Pharmaceutica AG | 56 | |
| Caroline MD | Lonza Group AG | 51 | |
| Dietrich Stber | Basilea Pharmaceutica AG | N/A | |
| Aurelio Sahagun | Straumann Holding AG | 50 | |
| Rahma Samow | Straumann Holding AG | 44 | |
| Maria Nunez | Lonza Group AG | N/A | |
| PierreAlain Ruffieux | Lonza Group AG | 54 | |
| David Veitch | Basilea Pharmaceutica AG | 58 | |
| O Mller | VAT Group AG | N/A | |
| Dirk Oehlers | Lonza Group AG | N/A | |
| Victoria Morgan | Lonza Group AG | N/A | |
| U Gantner | VAT Group AG | N/A | |
| Michael Allison | VAT Group AG | 61 | |
| Constance Ward | Lonza Group AG | N/A | |
Management Performance
| Return On Equity | -8.4 | |||
| Return On Asset | -0.16 |
Newron Pharmaceuticals Leadership Team
Elected by the shareholders, the Newron Pharmaceuticals' board of directors comprises two types of representatives: Newron Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Newron. The board's role is to monitor Newron Pharmaceuticals' management team and ensure that shareholders' interests are well served. Newron Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Newron Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ravi Anand, Chief Officer | ||
| Roberto Galli, VP Fin | ||
| Stefan Weber, CEO Director | ||
| Marco Caremi, Exec Devel |
Newron Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Newron Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -8.4 | |||
| Return On Asset | -0.16 | |||
| Profit Margin | (2.44) % | |||
| Operating Margin | (1.84) % | |||
| Current Valuation | 32.84 M | |||
| Shares Outstanding | 17.85 M | |||
| Shares Owned By Insiders | 4.96 % | |||
| Shares Owned By Institutions | 7.28 % | |||
| Price To Earning | (11.88) X | |||
| Price To Book | 7.98 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Newron Stock Analysis
When running Newron Pharmaceuticals' price analysis, check to measure Newron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Newron Pharmaceuticals is operating at the current time. Most of Newron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Newron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Newron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Newron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.